Cizzle Brands Achieves Double-Digit Growth For All CWENCH Hydration SKUs Across Top North American Accounts

Cizzle Brands Achieves Double-Digit Growth For All CWENCH Hydration SKUs Across Top North American Accounts

Among North American key accounts for the Company, retailers and distributors have been placing re-orders for CWENCH Hydration™, on average, once per week throughout the first half of this fiscal year. This recurring pace of re-orders clearly demonstrates strong distribution and a high velocity of in-store sales.

Cizzle Brands Corporation (Cboe Canada: CZZL) (OTCQB: CZZLF) (Frankfurt: 8YF) ( the "Company" or "Cizzle Brands") , is pleased to provide investors with an update on sales traction for its flagship product, CWENCH Hydration™ . Since the start of the Company's fiscal year (August 1, 2024), CWENCH Hydration™ has outperformed initial expectations as the brand continues to be commercialized across Canada and the United States.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250306779889/en/

CWENCH Hydration™ continues its strong performance across North America in 2025 (Photo: Business Wire)

CWENCH Hydration™ continues its strong performance across North America in 2025 (Photo: Business Wire)

To date, every retailer that is carrying CWENCH Hydration has placed at least one re-order within two months of carrying the product. Among four of the Company's key North American accounts, re-orders are being submitted, on average, once per week, with 111 cumulative wholesale orders from these four key accounts since August 1, 2024.

Cizzle Brands' President and Chief Revenue Officer Tucker Wright commented, "As we strategically introduce CWENCH Hydration™ to the market with key retail partners and cultivate a sustained sales pipeline through these channels, we can attribute this re-order rate to several factors. Foremost is the quality of the product, which we believe speaks for itself as customers come back to the store to buy more CWENCH after purchasing it for the first time. This is part of a broader trend, in which there is growing demand for premium healthy hydration options for athletes of all ages… and CWENCH's key differentiators – all-natural, low-sugar, non-plastic packaging – is helping it to excel in the category. Additionally, robust distribution logistics and prominent in-store marketing ( e.g. , endcap displays and point-of-sale materials) have helped to solidify an efficient operations cycle from the point of manufacture to the point of consumption. We will continue to scale the footprint of CWENCH Hydration™ using this playbook, and we are very pleased with the results achieved to date in this fiscal year."

In the Company's largest account in Canada (a national sporting goods retailer with over 100 locations), unit sales of the two Hydration Mix versions of CWENCH Hydration™ have grown by 72% 1 (10-Count) and 64% 2 (315-gram) sequentially from the first quarter of the present fiscal year (three-month period from August 1 2024 to October 31, 2024) to the second quarter of the present fiscal year (three-month period from November 1 2024 to January 31, 2025).

Similarly, unit sales of all four Ready-to-Drink ("RTD") flavours of CWENCH Hydration™ at Cizzle Brands' largest U.S. account (an upscale chain of fitness centres with over 100 locations throughout the United States) grew by 39% 3 from September of 2024 through January of 2025.

Cizzle Brands' Founder, Chairman, and Chief Executive Officer John Celenza commented, "Having launched CWENCH Hydration™ in May of 2024, the product has proven itself remarkably well in the Canadian and U.S. marketplaces, which has been sustaining our brand growth and product re-order rate while maintaining strong margins. As a healthy hydration option for athletes of all ages, the visibility of the CWENCH Hydration™ brand at the grassroots level has been instrumental to our growth. With orders coming in from athletes and trainers across professional sports teams and Division 1 colleges along with our support of 500 youth hockey teams representing over 12,000 youth hockey players across North America, these factors have helped to establish a substantial presence for CWENCH in the world of sports. Adults, teens, and children are asking for CWENCH by name and are making it part of their hydration playbook. We are only getting started with building market share for CWENCH Hydration™, and I believe that these early-stage reorder rates provide us with a growing confidence in terms of what is on the horizon for CWENCH and Cizzle Brands."

About Cizzle Brands Corporation

Cizzle Brands Corporation is a sports nutrition company that is elevating the game in health and wellness. Through extensive collaboration and testing with leading athletes and trainers across several elite sports, Cizzle Brands has launched two leading product lines in the sports nutrition category: (i) CWENCH Hydration™, a better-for-you sports drink that is now carried in over 1,200 stores in Canada, the United States, and Europe; and (ii) Spoken Nutrition, a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport® qualification. All Cizzle Brands products are designed to help people achieve their best in both competitive sports and in living a healthy, vibrant, active lifestyle.

For more information about Cizzle Brands, please visit: https://www.cizzlebrands.com/

For more information about CWENCH Hydration™, please visit: https://www.cwenchhydration.com

Notice Regarding Images and Links: This press release may contain images and/or links to outside web pages, which could play an important role in providing the full context of the news update being conveyed through this press release. Some news aggregation services may remove these images and/or links at their discretion. Therefore, readers are encouraged to access SEDAR+ or the News section of the Cizzle Brands Corporation website to view this press release containing all images and/or links as originally published.

On behalf of the Board of Directors of the Company,

Cizzle Brands Corporation

"John Celenza"

John Celenza, Founder, Chairman, and Chief Executive Officer

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This news release contains "forward-looking information" which may include, but is not limited to, information with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future, such as, but not limited to: new products of the Company and potential sales and distribution opportunities. Such forward-looking information is often, but not always, identified by the use of words and phrases such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company.

Forward looking information involves known and unknown risks, uncertainties and other risk factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks include risks related to increased competition and current global financial conditions, access and supply risks, reliance on key personnel, operational risks, regulatory risks, financing, capitalization and liquidity risks. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company undertakes no obligation, except as otherwise required by law, to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors change.

Footnotes

1 72% sequential growth of CWENCH Hydration™ 10-count units sold from Cizzle Brands' Fiscal Q1 2025 to Fiscal Q2 2025 reflects unit sales increasing from 11,943 units to 20,543 units each quarter with this account

2 64% sequential growth of CWENCH Hydration™ 315-gram units sold from Cizzle Brands' Fiscal Q1 2025 to Fiscal Q2 2025 reflects unit sales increasing from 2,730 units to 4,478 units each quarter with this account

3 39% sequential growth of CWENCH Hydration™ RTD beverage units sold during the calendar month of September 2024 compared to the calendar month of January 2025 with this account reflects unit sales increasing from 11,695 units per month to 16,280 units per month

For further information, please contact:

Setti Coscarella
Head of Corporate Development
investors@cizzlebrands.com
1-844-588-2088

News Provided by Business Wire via QuoteMedia

CZZL:AQL
The Conversation (0)
Cizzle Brands Expands Availability of CWENCH Hydration at all Fortinos Locations in Ontario

Cizzle Brands Expands Availability of CWENCH Hydration at all Fortinos Locations in Ontario

Approximately two months after the chain-wide launch of CWENCH's hydration mix powder in Fortinos stores (February of 2025), CWENCH Hydration™ is now fully represented at Fortinos with the addition of its ready-to-drink Tetra Pak® format at all Fortinos locations, strengthening the footprint of CWENCH Hydration™ in key Ontario population centres where the Company is strategically commercializing its flagship product line.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cizzle Brands Strengthens U.S. Footprint of CWENCH Hydration With Availability at United Supermarkets in Texas

Cizzle Brands Strengthens U.S. Footprint of CWENCH Hydration With Availability at United Supermarkets in Texas

The placement of CWENCH Hydration™ at United Supermarkets, a well-known chain of supermarkets in central and northern Texas, is part of Cizzle Brands' plan to strategically add to its U.S. presence in 2025.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cizzle Brands Announces that All 134 Metro Locations in Ontario Will be Offering CWENCH Hydration Ready-to-Drink Beverages

Cizzle Brands Announces that All 134 Metro Locations in Ontario Will be Offering CWENCH Hydration Ready-to-Drink Beverages

The availability of CWENCH Hydration™ in its ready-to-drink format at all 134 Metro locations in Ontario follows only three months after the initial launch of CWENCH's Hydration Mix with Metro in its Ontario stores.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cizzle Brands' CWENCH Hydration Becomes USA Hockey's Official Hydration Partner

Cizzle Brands' CWENCH Hydration Becomes USA Hockey's Official Hydration Partner

As a proud supporter of grassroots hockey across North America, Cizzle Brands is embracing this opportunity to further enhance its U.S. presence with brand visibility throughout the entire USA Hockey network by virtue of this multi-year sponsorship.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cizzle Brands Adds to its Presence in Ontario with Placements of CWENCH Hydration in Healthy Planet and Farm Boy

Cizzle Brands Adds to its Presence in Ontario with Placements of CWENCH Hydration in Healthy Planet and Farm Boy

The availability of CWENCH Hydration™ in Healthy Planet and Farm Boy, both of which are leading retailers in Ontario, will further enhance visibility and availability of the product as its market share continues to increase.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Double helix DNA with word "ETFs" and biotech stock tickers.

5 Small-cap Biotech ETFs to Watch

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one vehicle.

ETFs are a popular choice as they allow investors to enter the market more safely compared to investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

Below the Investing News Network takes a look at five small-cap biotech ETFs. The funds were selected using ETFdb.com, and their total assets under management (AUM) were under US$100 million as of May 20, 2025.

Keep reading...Show less
ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Radiopharm Theranostics (ASX:RAD; NASDAQ: RADX "Radiopharm"), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced the signing of a supply agreement that will provide Radiopharm with ITM's medical radioisotope, non-carrier-added Lutetium-177 (n.c.a. 177 Lu), to enable its usage in the clinical and potential future commercial development of the 177 Lu-based molecules in Radiopharm's development pipeline.

Under the terms of the agreement, Radiopharm will use ITM's n.c.a. 177 Lu across its clinical pipeline, including in key programs such as RAD 204 (PD-L1-targeting nanobody, Phase 1), RAD 202 (HER2-targeting nanobody, Phase 1), and RV01 (B7-H3-targeting monoclonal antibody, preclinical), for the treatment of solid tumors. Coupled with the targeting molecules that are designed to deliver ITM's n.c.a. 177 Lu directly to tumor sites, the radioisotope emits therapeutic beta radiation with the aim to destroy malignant cells in a highly precise and localized manner.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE

AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE

- Amgen (NASDAQ:AMGN) will present at the 2025 RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on Wednesday May 21, 2025. Kave Niksefat senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee

Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee

DSMC concluded that Phase 1 study may continue as planned without any modifications

On track to complete the enrollment of the first two cohorts by mid-2025

Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, announced today that it has achieved a key milestone in its ongoing clinical development program for its clinical-stage radiotherapeutic asset, 177Lu-RAD204, as the Data and Safety Monitoring Committee (DSMC) has approved to proceed to the next dose in its Phase 1 clinical trial in patients with PD-L1 positive advanced cancers 1 . The DSMC is an independent multidisciplinary group that conducts detailed reviews of unblinded study data, discusses potential safety concerns and provides recommendations regarding trial continuation.

"We greatly appreciate the DSMC's judicious review of our first cohort of patients in the Phase 1 study of 177Lu-RAD204, which allows us to advance to the higher dose cohort in a variety of PD-L1- driven cancers," said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. "With this clearance from the DSMC, the increased number of active centers and expansion to multiple tumor types beyond Non-Small Cell Lung Cancer (NSCLC), we expect to accelerate our timelines for complete enrolment of the next cohort by mid-2025. We believe that RAD204 has the potential to strongly improve clinical outcomes for patients with PD-L1 positive advanced cancers and we look forward to seeing data from the first two cohorts of patients later this year."

The DSMC reviewed the first cohort of four patients treated with 30mCi of 177Lu-RAD204 and confirmed that there was positive safety, pharmacokinetic and biodistribution data and agreed that the study may continue without modifications. The second cohort of patients will start at 60mCi of Lu177 rather than 40mCi previously assumed in the protocol. The second cohort of patients is expected to be enrolled by mid-year 2025 and will include expansion to multiple tumor types including NSCLC, Small-Cell Lung Cancer (SCLC), Triple-negative Breast Cancer (TNBC), Cutaneous Melanoma, head and neck squamous cell carcinoma (HNSCC) and Endometrial Cancer.

There are currently four clinical trial sites actively screening and recruiting patients in Australia.

About 177Lu-RAD204:

RAD204 is a single-domain monoclonal antibody (sdAb) that targets PD-L1, a protein that helps control the immune system and is overexpressed in many solid cancers, making it an attractive therapeutic target in multiple tumor types, including NSCLC, SCLC, TNBC, Cutaneous Melanoma, HNSCC, and Endometrial Cancer. Previously published Phase I imaging data of 16 NSCLC patients with 99Tc-RAD204 demonstrated that the diagnostic compound is safe and is associated with acceptable dosimetry 2 .

Tumor targeting with radioimmunotherapies such as 177Lu-RAD204 has the potential to address resistance mechanisms to current standard-of-care treatment options.

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain. Learn more at radiopharmtheranostics.com .

Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.

For more information:

Investors:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Anne Marie Fields
Precision AQ (formerly Stern IR)
E: annemarie.fields@precisionaq.com

Media:
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
X – https://x.com/TeamRadiopharm
LinkedIn – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

Ă—